Aberdare gp iii llc - by aberdare partners iii l p investment history in Conatus pharmaceuticals inc

Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 120 shares remaining shares owned 120

Warrant To Purchase Common Stock Conatus Pharmaceuticals Inc Cnat exercise price 7.43 has valueitem expiration due date 2018-05-30 underlying security shares 120 underlying security title Common Stock

f7 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase series b preferred stock were converted into warrants to purchase common stock with an exercise price of $7.43 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f8 the warrant is immediately exercisable.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 997 shares remaining shares owned 0

Warrant To Purchase Series B Preferred Stock Conatus Pharmaceuticals Inc Cnat exercise date 2018-05-30 exercise price 0.90 has valueitem expiration due date 2018-05-30 underlying security shares 997 underlying security title Series B Preferred Stock

f7 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase series b preferred stock were converted into warrants to purchase common stock with an exercise price of $7.43 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 1727 shares remaining shares owned 0

Warrant To Purchase Common Stock Conatus Pharmaceuticals Inc Cnat exercise date 2013-07-30 exercise price 0.0825 has valueitem expiration due date 2013-07-30 underlying security shares 1727 underlying security title Common Stock

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 1727 shares remaining shares owned 1727

Warrant To Purchase Common Stock Conatus Pharmaceuticals Inc Cnat exercise date 2013-07-30 exercise price 0.0825 has valueitem expiration due date 2013-07-30 underlying security shares 1727 underlying security title Common Stock

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 5701 shares remaining shares owned 0

Warrant To Purchase Series A Preferred Stock Conatus Pharmaceuticals Inc Cnat exercise price 0.01 has valueunderlying security shares 5701 underlying security title Series A Preferred

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f6 the warrant was immediately exercisable and was originally scheduled to expire on october 15, 2020, subject to its earlier termination upon the completion of the issuer's initial public offering or certain mergers, acquisitions or similar transactions.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 8552 shares remaining shares owned 0

Warrant To Purchase Series A Preferred Stock Conatus Pharmaceuticals Inc Cnat exercise price 0.01 has valueunderlying security shares 8552 underlying security title Series A Preferred

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.
f5 the warrant was immediately exercisable and was originally scheduled to expire on march 5, 2020, subject to its earlier termination upon the completion of the issuer's initial public offering or certain mergers, acquisitions or similar transactions.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 137626 shares remaining shares owned 0

Series B Preferred Stock Conatus Pharmaceuticals Inc Cnat underlying security shares 16682 underlying security title Common Stock

f1 each share of series a preferred stock and series b preferred stock automatically converted into shares of the issuer's common stock at the closing of the issuer's initial public offering ("ipo") at a conversion rate of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration. the shares of preferred stock had no expiration date.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 246775 shares remaining shares owned 0

Series A Preferred Stock Conatus Pharmaceuticals Inc Cnat underlying security shares 29912 underlying security title Common Stock

f1 each share of series a preferred stock and series b preferred stock automatically converted into shares of the issuer's common stock at the closing of the issuer's initial public offering ("ipo") at a conversion rate of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration. the shares of preferred stock had no expiration date.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 2470 shares at $11.00 remaining shares owned 52419

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: P Open market or private purchase of securities

f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 251 shares at $11.00 remaining shares owned 49949

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f4 the common stock was acquired upon conversion of a convertible promissory note exempt from the definition of derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the ipo.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 14 shares at $11.00 remaining shares owned 49698

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: S Open market or private sale of securities

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 1727 shares at $0.0825 remaining shares owned 49712

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: X Exercise of in-the-money or at-the-money derivatives securities (usually options)

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 46594 shares at $0 remaining shares owned 47985

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: C Conversion of derivative security (usually options)

f1 each share of series a preferred stock and series b preferred stock automatically converted into shares of the issuer's common stock at the closing of the issuer's initial public offering ("ipo") at a conversion rate of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration. the shares of preferred stock had no expiration date.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 104952 shares at $11.00 remaining shares owned 2226944

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: P Open market or private purchase of securities

f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 10614 shares at $11.00 remaining shares owned 2121992

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f4 the common stock was acquired upon conversion of a convertible promissory note exempt from the definition of derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the ipo.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc sold 552 shares at $11.00 remaining shares owned 2111378

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: S Open market or private sale of securities

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 73395 shares at $0.0825 remaining shares owned 2111930

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: X Exercise of in-the-money or at-the-money derivatives securities (usually options)

f3 upon the conversion of all outstanding shares of preferred stock of the issuer in connection with the closing of the ipo, the warrants to purchase shares of series a preferred stock were converted to warrants to purchase common stock with an exercise price of $0.0825 per share, at a ratio of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration, and were then net exercised based on the ipo price of $11.00 per share.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2013-08-01 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-13-038817.txt Sec File: edgar/data/1582419/0001209191-13-038817-index.htm

2013-07-30 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Partners Iii L P

Invested in Conatus Pharmaceuticals Inc bought 1979321 shares at $0 remaining shares owned 2038535

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: C Conversion of derivative security (usually options)

f1 each share of series a preferred stock and series b preferred stock automatically converted into shares of the issuer's common stock at the closing of the issuer's initial public offering ("ipo") at a conversion rate of 1 share of common stock for every 8.25 shares of preferred stock, rounded down to the nearest whole number, for no additional consideration. the shares of preferred stock had no expiration date.
f2 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.